Water-soluble substituted chitosan derivatives as technology platform for inhalation delivery of siRNA by Capel, Victoria et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1080/10717544.2018.1440668
Document Version
Publisher's PDF, also known as Version of record
Link to publication record in King's Research Portal
Citation for published version (APA):
Capel, V., Vllasaliu, D., Watts, P., Clarke, P., Luxton, D., Grabowska, A., ... Stolnik , S. (2018). Water-soluble
substituted chitosan derivatives as technology platform for inhalation delivery of siRNA. DRUG DELIVERY, 644-
653. DOI: 10.1080/10717544.2018.1440668
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 12. Mar. 2018
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=idrd20
Drug Delivery
ISSN: 1071-7544 (Print) 1521-0464 (Online) Journal homepage: http://www.tandfonline.com/loi/idrd20
Water-soluble substituted chitosan derivatives
as technology platform for inhalation delivery of
siRNA
Victoria Capel, Driton Vllasaliu, Peter Watts, Philip A. Clarke, Dominic
Luxton, Anna M. Grabowska, Giuseppe Mantovani & Snjezana Stolnik
To cite this article: Victoria Capel, Driton Vllasaliu, Peter Watts, Philip A. Clarke, Dominic Luxton,
Anna M. Grabowska, Giuseppe Mantovani & Snjezana Stolnik (2018) Water-soluble substituted
chitosan derivatives as technology platform for inhalation delivery of siRNA, Drug Delivery, 25:1,
644-653, DOI: 10.1080/10717544.2018.1440668
To link to this article:  https://doi.org/10.1080/10717544.2018.1440668
© 2018 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
View supplementary material 
Published online: 01 Mar 2018. Submit your article to this journal 
Article views: 74 View related articles 
View Crossmark data
RESEARCH ARTICLE
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Giuseppe Mantovania and Snjezana Stolnika
aDivision of Molecular Therapeutics and Formulation, School of Pharmacy, University of Nottingham, University Park, Nottingham,
United Kingdom; bArchimedes Development Limited, Albert Einstein Centre, Nottingham Science and Technology Park, University Boulevard,
Nottingham, United Kingdom; cDivision of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham,
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ABSTRACT
Despite research efforts full potential of siRNA-based therapeutics has not yet been fully realized due
to a need for suitable, effective delivery formulations. Here, we examine a potential of a new class of
water-soluble chitosans as siRNA platform for pulmonary delivery. The system is based on piperazine-
substituted chitosans, a material designed to integrate established, safe application of chitosan for
mucosal administration with novel properties: the piperazine-substituted chitosans are freely water-sol-
uble at physiological pH, possess low cytotoxicity (no significant reduction in cell viability up to
0.1mg/ml), and provide efficient incorporation of siRNA into sub-300 nm colloidal complexes (at rela-
tively low polymer/siRNA ratio of 5:1). In vitro, the complexes achieved silencing of a model gene at a
level of 40–80%, when tested in a panel of lung epithelial cells. Considering the formulation
‘developability’, there were no significant changes in the complexes’ size and integrity on aerosolisa-
tion by microsprayer (PenCenturyTM) device. Following intratracheal aerolisation, the complexes depos-
ited throughout the lung, although relatively inhomogeneously, as judged from IVIS imaging of the
isolated mouse lung (visualizing DY647-siRNA). In vivo data illustrate absence of adverse effects on
repeated administration of complexes and significant tumor reduction in atopical lung cancer model in
mice. Altogether, the data illustrates potential of substituted chitosan derivatives to be utilized as a
safe system for inhalation delivery of siRNA.
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Introduction
RNA interference is a natural phenomenon mediated by short
21–23 bp RNAs (siRNA), which is being exploited to selectively
silence genes involved in disease. This rapidly expanding area
has led to studies with therapeutics siRNA for a range of dis-
eases, including HIV, respiratory viruses, and cancer. Effective
delivery, however, remains the most significant barrier to real-
izing the full potential of siRNA silencing in clinic. Cationic pol-
ymers have been used to incorporate siRNA via electrostatic
interactions into nano-sized complexes; including studies
employing chitosan. Chitosan is ‘generally considered as safe’
(GRAS) pharmaceutical excipient, and has previously been
studied for siRNA delivery to the lung; chitosan-siRNA nano-
particles (formulated at N:P ratio of 23:1) were administered
intranasally to EGFP-expressing transgenic mice and resulted
in a 43% reduction of EGFP expression in the bronchioles,
compared to the untreated control (Howard et al., 2006).
However, a limitation to formulation developability of
chitosan is its poor solubility at physiological pH (Katas &
Alpar, 2006). To overcome this problem, chitosan derivatives
have been developed by, for example, modifications of either
free primary amine groups to create quaternary ammonium
products of chitosan, such as trimethyl chitosan (TMC), or
chain PEGylation (Casettari et al., 2010), with both approaches
increasing the product’s water solubility. Here, we investigated
a family of piperazine-substituted chitosans, a material aimed
to integrate established application of chitosan for mucosal
administration (Casettari et al., 2010), with improved develop-
ability as siRNA delivery agent, based on their water solubility
at physiological pH.
We tested the potential of piperazine-chitosans in siRNA
silensing of EGFR, a pro-angiogenic factor up-regulated in
non-small cell lung cancer (NSCLC), one of the most malig-
nant forms of lung cancer. EGFR provides an essential sur-
vival signal to tumor cells through the activation of the
expression of anti-apoptotic factors such as Akt and protein
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kinase C (Shen & Kramer, 2004). Unfortunately, therapies such
as anti-angiogenesis monoclonal antibodies or tyrosine kinase
inhibitors have failed to show significant advantages over
chemotherapy and have failed to improve long-term patient
survival (Martinelli et al., 2009). The siRNA therapy to silence
EGFR offers a potential alternative, however, ‘naked’ siRNA
delivery to the lung has not proven efficient (Moschos et al.,
2007). In the presenct work, we appreciated a need for a
delivery system to protect siRNA from a relatively high levels
of RNase activity in the lung (ThermoFisher Scientific, 2017), as
well as poor cellular internalization. Water soluble substituted
chitosan-siRNA complexes were formulated with the product
attributes appropriate for the development of an inhalation
formulation, while low N:P ratio (5:1) was aimed at reducing
the lung burden of an excess of siRNA condensing material.
Materials and methods
Water-soluble piperazine chitosan derivatives were provided
by Archimedes Pharma (Nottingham, UK). Water-soluble
piperazine chitosan derivatives were provided for this study
by Archimedes Pharma (UK). These were supplied, synthe-
sized, and characterized, as described previously, by (Holappa
et al., 2006). The structural characterization and physicochem-
ical properties of modified chitosans used in the study are
summarized in Figure S1 and Table 1. GAPDH-specific siRNA
was purchased from Dharmacon (CO, USA). Lipofectamine
2000 was purchased from Invitrogen (Paisley, UK) and used
as per supplier’s instructions. All other chemicals, unless
otherwise stated, were obtained from Sigma-Aldrich (Poole,
UK). H1299, A549, and Calu-3 cell lines were purchased from
the American Type Culture Collection (ATCC, Manassas, VA,
USA). H1299 cells were routinely cultured in RPMI-1640
medium supplemented with 10% v/v fetal bovine serum, 1%
v/v penicillin/streptomycin, and 1% v/v L-glutamine at 37 C/
5% CO2. A549 and Calu-3 cells were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) and Eagle’s minimal essen-
tial medium (EMEM, Sigma-Aldrich, Dorset, UK) respectively,
supplemented as previous. EMEM was further supplemented
with sodium pyruvate (1% v/v). GAPDH targeting siRNA
(50-UGGUUUACAUGUUCCAAUAUU-30 (sense), 3’UUACCAAA
UGUACAAGGUUAU P-5’ (antisense)) was purchased from
Dharmacon (UK).
Silencer Cy3TM and DY647TM labeled siRNA targeting
GAPDH was purchased from Thermo Fischer Scientific. EGFR
(50-CACAGUGGAGCGAAUUCCU-30) ONTARGETplus in vivo
siRNA and negative control siRNA were purchased from
Dharmacon (UK).
Formation of substituted-chitosan – siRNA complexes
Complexes were prepared in Tris-HCl buffer (10mM, pH 7.4)
by adding equal volumes of polymer to siRNA solutions to
Table 1. Structures and properties of piperazine chitosans used in the study.
Piperazine substituent of chitosan
Polymer
name
Degree of
substitution (%) Mw (kDa) Mn (kDa) Mw/Mn
Average
monomer charge1
Calculated 1:1
charge ratio2
NQ30 30 42.9 24.7 1.73 0.33 3.03
NQ60 60 35.0 16.6 2.09 0.60 1.67
MQ4-42 42 34.5 17.4 1.98 0.46 2.16
MQ4-87 87 28.6 17.2 1.66 0.87 1.15
MQ1-46 46 39.2 20.4 1.92 0.50 2.00
MQ1-85 85 34.2 21.8 1.57 0.85 1.18
DQ39 39 24.0 39.5 1.65 0.83 1.21
DQ56 56 33.5 32.1 1.04 1.15 0.87
All substituted chitosans have degree of deacetylation of 85%. NQ: non-quaternarised, MQ1: mono-quaternary, center on the 1-position of piperazine ring; MQ4:
mono-quaternary, center on the 4-position of piperazine ring; DQ: di-quaternary substitution. Numeric value in the name refers to the percentage piperazine
substitution.1 Estimated from polymer composition2 Calculated assuming protonation in pH 7.4 buffer as discussed in the text.
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give the calculated monomer:nucleotide ratio:
Mass polymer ¼ Mw polymer RU
Mw siRNA RU
 ratio  mass siRNA
where ‘RU’ refers to the average molecular weight of the
repeating unit of the polymer or siRNA. It should be noted
that in a subsequent text substituted-chitosan to siRNA ratios
are not defined, as generally used, charge per charge ratio
(N:P), but rather as monomer per siRNA nucleotide ratio
(M:N). This is due to the fact that protonation of both unsub-
stituted chitosan ‘backbone’ monomers, and substituted
piperazine ring, is pH dependent, meaning that the polymers’
charge density will be dependent on their environment.
Ethidium bromide displacement assay
Ethidium bromide (EtBr) (4 ml, 1mg/ml) was added to a
cuvette containing 10mM Tris-HCl (1ml) and fluorescence
measured (Hitachi F-4500 fluorescence spectrophotometer) at
kex560 and kem 605 nm. siRNA solution (10mg) was
then added and fluorescence recorded. Polymer solutions
(1mg/ml) were added into the cuvette in a stepwise manner
to give the required monomer:nucleotide ratio. After each
polymer addition, samples were gently agitated, followed by
fluorescence measurements for 2–3minutes. Sample meas-
urements were carried out in triplicates. The fluorescence for
each ratio was calculated relative to the maximum fluores-
cence for the EtBr-siRNA solution and corrected for the back-
ground fluorescence of EtBr using the following equation:
Relative fluorescence %ð Þ ¼ fpolyplex  fEtBr
fsiRNA  fEtBr
 100
where ‘fEtBr’ is the fluorescence of EtBr in buffer, ‘fsiRNA’ is
the fluorescence of EtBr plus siRNA in buffer, and ‘fcomplex’ is
the fluorescence of EtBr plus complex in buffer:
Agarose gel electrophoresis
Aliquots of polymer solution were added to the siRNA solu-
tion (1 lg). Complexes were prepared as described above
over the following range of monomer:nucleotide molar ratios:
0.25:1, 0.5:1, 0.75:1, 1:1, 1.25:1, 1.5:1, 1.75:1, 2:1, and 5:1. Free
polymer and free siRNA served as controls. The samples were
briefly mixed by vortexing and incubated at room tempera-
ture for 30min. Loading buffer (2 ll) was added to the
samples and loaded into 1.2% agarose gel containing EtBr
(1lg/ml). Electrophoresis was carried out at 80 V in 1X
Tris-acetate-EDTA buffer (pH 7.4) for 1 hr. The siRNA bands
were visualized under UV transillumination. Polymer bands
were stained by immersing the gel in staining solution
(10/50/40 glacial acetic acid, methanol, double distilled water,
1% w/v Coomassie blue) for 1 hour, followed by washing
with destaining solution (10/10/80 glacial acetic acid, metha-
nol, double distilled water) overnight.
Particle size analysis
The mean hydrodynamic diameter and particle size distribu-
tion of polymer-siRNA complexes was determined by
dynamic light scattering (DLS) using a Viscotek 802 system
(Malvern Instruments , UK). Complexes were suspended in
10mM Tris-HCl buffer (pH 7.4). The results are expressed as
the mean of three separate measurements, with each meas-
urement showing a mean value of 10 runs. All measurements
were carried out at 25 C.
Release of siRNA from complexes
Agarose gels were prepared at a concentration of 1.2% w/v
in 1X TBE buffer containing 0.5 lg/ml ethidium bromide.
Polyplexes (20 ll) containing 1 lg of siRNA at a 5:1 ratio were
formed over 24 hours. L-glutathione 2.5mM (9.22 lL, 5mg/ml
solution) was added to the polyplexes formed with thiolated
polymer, and they were incubated at 37 c for 30minutes.
Following this, heparin was added to certain polyplexes at
concentrations of 0.1 U heparin/lg siRNA (6 lL, 0.5mg/ml)
and 0.2U heparin/lg siRNA (6lL, 0.25mg/ml), followed by
gel electrophoresis assay.
Cell toxicity assays
The effects of piperazine chitosans on cellular metabolic
activity (indicator of cell viability) was determined by an MTS
assay. H1299 cells were cultured on 96-well plates (10,000
cells/well) for 24 hours. The culture medium was replaced
with serum-free medium containing polymer solutions
(0.0001–1mg/ml) and cells were incubated with the samples
for 4 hours. Samples were removed and the MTS assay was
carried out according to supplier’s instructions. Results are
given as mean values of eight repeats (± SD). IC50 values
were calculated using GraphPad Prism by non-linear
regression.
Toxicity of DQ39 polymer was futher tested in H1299,
A549, and Calu-3 cells. Cells were cultured on 96-well plates
(104 cells/well) for 24 hours prior to the toxicity study.
Culture medium was then replaced with serum-free equiva-
lents (RPMI-1640, DMEM or EMEM, respectively) containing
polymer solutions (0.0001–1mg/ml) and incubated for cells
were incubated with the samples for 4 hours. Samples were
removed and MTS assay conducted according to supplier’s
instructions. Relative cell viability was calculated via compari-
son with cells treated with culture medium or 0.2% v/v
Triton-X (as negative or positive controls, respectively).
Results are given as mean values (n¼ 8). Half maximal inhibi-
tory concentration (IC50) values were calculated with
GraphPad Prism by non-linear regression.
In vitro silencing of a model gene
H1299 cells were seeded on 24-well plates (105 cells/well)
and cultured to 70% confluence. siRNA-substituted chitosan
complexes (corresponding 100 nM siRNA) were added to the
cells in serum-free medium (HBSS:HEPES pH 7.4) and incu-
bated for up to 4 hours. Samples were then removed and
replaced with fresh culture medium and cells cultured for 44
hours. GAPDH activity was analyzed using the KDalert
GAPDH kit (Ambion, USA), following the supplier’s protocol,
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as a commonly used knock-down assay. Relative GAPDH
activity was calculated against untreated cells.
Droplet size and spray pattern analysis
Droplet-size analysis of aerosols was conducted by laser dif-
fraction using a Malvern SpraytecVR (Malvern, UK) with RT Sizer
software. Actuation of the microsprayer was conducted manu-
ally, at a distance of 4 cm from the laser beam. All measure-
ments were made at room temperature (20–23 C). The focal
length of the lens used was 100mm, with a corresponding
droplet-size range of 0.5–200 lm. The refractive index and
absorption coefficient settings were a media refractive index of
1.00þ 0.00i (air) and particulate refractive index of 1.33þ 0.00i
(water). Data is reported as volume diameter defined by 10%,
50% (volume median), and 90% of the cumulative volume
undersize; Dv10, Dv50, and Dv90, respectively.
The spray pattern from the microsprayer was visualized by
spraying formulations containing a dye onto TLC paper. The
minimum and maximum diameters of the spray pattern were
measured by digital calipers. The spray pattern was charac-
terized by determining the ‘effective diameter’ and ovality.
‘Effective diameter’ was defined as the averages of the max-
imum and minimum diameters of three sprays and the oval-
ity was expressed as the maximum diameter divided by the
minimum diameter.
In vitro toxicity to A549-luc cells
The effects of EGFR targeted siRNA on the cell toxicity to
A549 luciferase expressing cells (A549-luc) in vitro was meas-
ured by MTS viability assay. A549-luc cells were seeded on
96-well plates at 104 cells/well and cultured for 24 hours.
DQ39-siRNA complexes (formulated at a 5:1M:N ratio) con-
taining EGFR targeted siRNA, or negative control siRNA, were
added to cells in serum-free culture medium 100 nM siRNA/
well. After 4 hours, the complexes were removed and
replaced with fresh serum-containing medium. Cells were
incubated for a further 24, 48, or 72 hours, after which cell
survival was measured by an MTS assay.
In these experiments, doxorubicin was employed for com-
parison. Doxorubicin was added to the cells (cultured as
above) at 5mM and cells were incubated for 24, 48, or 72
hours. After each time point, the samples were removed and
an MTS assay carried out, as described above.
In vivo studies
Animal studies were conducted under the UK Home Office
Licence number PPL 40/3559, 19 b (3). NCRI guidelines for
the welfare and use of animals in cancer research, and LASA
good practice guidelines and FELASA working group on pain
and distress guidelines were followed. Male MF-1 nude mice
at six to seven weeks of age were obtained from Charles
River, Harlow, UK. Mice were maintained in individually venti-
lated cages (Tecniplast, UK) within a barriered unit illumi-
nated by fluorescent lights set to give a 12 hour light-dark
cycle as recommended in the United Kingdom Home Office
Animals (Scientific Procedures) Act 1986. The room was main-
tained at an air temperature range of 21 ± 2 C and a humid-
ity of 55%þ 10%. Mice were housed in social groups during
the procedure with irradiated bedding and provided with
autoclaved nesting materials and environmental enrichment.
Mice were terminated by an approved S1 method.
A549-luc tumor cells were suspended in standard formula-
tion of Matrigel at 2 106 cells per 100ll. Tumors were
established in MF-1 nude male mice by implanting subcuta-
neously into the left flank of each mouse. Tumor establish-
ment and growth was monitored during the experiment by
caliper measurements twice weekly, 2 D and 3D optical
imaging carried out under anesthesia in an IVIS Spectrum
weekly, and at termination, to provide an optical post mor-
tem. Tumor measurements and 3D image reconstruction
were made using Living Image (4.3.1 build) software (Caliper
Life Sciences Hopkinton, MA, USA). To quantify the fluores-
cent intensity, a fluorescent calibrated unit (termed radiant
efficiency), representing the fractional ratio of emitted pho-
tons per incident excitation photon, was used to compensate
for non-uniform excitation light pattern.
Dosing was initiated in established tumors, those whose
volume was demonstrably larger than the original implant-
ation volume. Treatment groups (n¼ 8 mice per group) were
as follows: (i) EGFR-siRNA-DQ39 complexes (10 mg siRNA,
intratumoral injection, twice weekly) and (ii) negative control
siRNA-DQ39 complexes (10mg siRNA, intratumoral injection,
twice weekly). All animals were sacrificed at the same time
when tumor volume reached the maximum permissible size
of 1.5 cm diameter in at least one mouse. Tumors were dis-
sected and preserved for immunohistochemical analysis.
Lung distribution
Male MF-1 nude mice, six to seven weeks old, were dosed
intratracheally by the Microsprayer Aerosolizer (Model IA-IC,
PennCentury, Philadelphia, PA, USA). Mice were anesthetized
with ketamine/medatomidine (Ket 0.9ml/Met 0.3ml/NaCl
8.8ml) dosed at 10 ml/g. Mice were restrained on the support
rig and the instillate administered intratracheally using a
Microsprayer Aerosoliser, guided by a pediatric otoscope.
Each dose contained 10 mg of siRNA in 50 ml. Imaging was
carried out in the IVIS Spectrum with parameters chosen for
DY647 and the closest red-shifted filter set. A ‘blue light’ con-
trol filter set was also used to provide auto-fluoresence data
for un-mixing and image analysis. For the lung IVIS analysis,
mice were culled by an approved S1 method post initial
imaging, while still under anesthetic; lungs were dissected
and imaged as described above.
Immunohistochemical analysis
Tumor xenograft sections (4mm) were dewaxed in two
sequential xylene washing, rinsed in three sequential metha-
nol baths, and rehydrated in running tap water. Staining for
EGFR was carried out using a modified Animal Research Kit
to prevent protein on protein interactions according to man-
ufacturer’s instructions (ARK, Dakocytomation, Agilent, Santa
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Clara, CA, USA): antigen retrieval was carried out by incuba-
tion with proteinase K, 0.05mol/L for 10minutes
(Dakocytomation). Endogenous peroxidase was blocked with
hydrogen peroxide, and tissue sections were incubated with
either biotinylated mouse monoclonal anti-human EGFR
(clone E30, 16.6mg/ml, Dakocytomation) or biotinylated
mouse IgG control serum (Dakocytomation) at matched con-
centrations for 60minutes. Each primary treatment was pre-
blocked with mouse protein blocking agent to the appropri-
ate concentration. Visualisation was via streptavidin-HRP sec-
ondary antibody for 15minutes, followed by liquid system
DAB chromogen for 5minutes. Sections were counterstained
with Mayer’s Haemalum and then dehydrated and cleared
through sequential methanol and xylene rinses and cover-
slipped with DPX adhesive (Sigma).
Analysis of staining was carried out by the H-score
method, which takes into account the percentage of tissue
stained and its staining intensity. Staining levels (percentage)
were divided into high, medium, and low intensity for each
region of interest and a multiplication factor (weighting) was
applied to each: 3 for high intensity, 2 for medium intensity,
and 1 for low intensity. These data were added to give the
H-Score value, which at its maximum will not exceed 300.
Statistical analysis
GraphPad Prism 7 software (La Jolla, CA, USA) was used for
data analysis. Comparisons between two groups were made
using independent samples Student’s t-test and one way
analysis of variance (ANOVA) was applied for the comparison
of three or more groups. Tukey’s multiple comparison test
(post-hoc) was used in conjunction with ANOVA to evaluate
differences in individual means in EGFR staining data. For
other experiments, Bonferroni post-hoc test was applied for
comparison of group means of three or more groups.
p Values of< .05 were considered statistically significant.
, , , and  indicate p< .05, p< .01, p< .001, and
p< .0001, respectively.
Results and discussion
In the present work, we assessed potentials of a new class of
water soluble, piperazine-substituted derivatives of chitosan,
as condensing agents for development of inhalable siRNA
delivery formulation. The piperazine derivatives were synthe-
sized and characterized as previously described (Holappa
et al., 2006) and summarized in Table 1. The derivatives vary
with respect to the structure of the piperazine substituent, as
well as the degree of substitution. These can be grouped
into four categories depending on the nature of the pipera-
zine substituent and location of the quaternary center as:
non-quaternarized (‘NQ’), mono-quaternary with center on
the 1-position of piperazine ring (‘MQ1’), mono-quaternary
with center on the 4-position of piperazine ring (‘MQ4’) and
di-quaternary (‘DQ’). In each of the four categories, deriva-
tives with a high and a low degree of piperazine substitution
were synthesized to investigate the effect of degree of sub-
stitution (in effect corresponding to a charge density),
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Figure 1. siRNA complexation by piperazine substituted chitosans. (A) EtBr displacement assays of piperazine substituted chitosans with siRNA. Polymers and EtBr
containing siRNA solutions in 10mM Tris-HCl buffer pH 7.4 mixed at specified at monomeric unit: nucleotide ratio; fluorescence level expressed as a% of the initial
relative fluorescence of the EtBr siRNA complex (n¼ 3). (B) Agarose gel electrophoresis. The upper image shows the migration of free polymer, and the lower image
shows the migration of free siRNA. The bands were visualized as described in the Methods section. Lane 1: siRNA control; lanes 2–9: polymer:siRNA complexes at
ratios 0.25, 0.5, 0.75, 1.0, 1.25, 1.5, 2.0, and 5.0 to 1; lane 10: polymer control. Polymers: gel a shows MQ1-46; b: MQ4-42; c: NQ30; and d: DQ39.
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in addition to the effects of structure of the substituent. The
polymers were designed to have similar molecular weights in
order to remove this variable from the study. It should be
noted that all substituted chitosan derivatives synthesized
are water-soluble materials at physiological pH, a clear
advantage over ‘un-modified’ chitosan from a product devel-
opability perspective.
Regarding the polymers’ ability to complex siRNA, an ini-
tial screening applying EtBr displacement assay (Figure 1(A))
illustrates that a plateau in siRNA complexation was achieved
at relatively low monomer:nucleotide ratios of approximately
5:1, and that variations in the complexation ability are related
to the piperazine-chitosan structural properties. For non-qua-
ternary and mono-quaternary derivatives, regardless of the
quaternary center position and degree of substitution, there
is generally a lower level of EtBr fluorescence reduction, rela-
tive to di-quaternary piperazine chitosans, suggesting a
higher siRNA binding affinity by the molecular structure of
the latter derivatives. A similar trend is seen in electrophor-
etic migration gel assay (Figure 1(B)) where di-quaternary
DQ39 derivative exhibited high-binding affinity for siRNA, as
judged from disappearance of free siRNA in the gel at rela-
tively low monomer:nucleotide ratios (0.5:1). However, the
presence of a relatively intense EtBr fluorescence in the appli-
cation wells for DQ39 complexes, even at monomer:nucleo-
tide ratios of 5:1, would indicate the formation of ‘loose’
complexes, which allow EtBr intercalation with siRNA. The
reasons for this may include an importance of ‘matching’
charge densities in polyelectrolyte interactions; two polyelec-
trolytes with ‘matching’ charge densities can form compact
complexes while the charge density ‘mismatching’ results in
the ‘swollen’ complexes (Hoogeveen et al., 1996; Danielsen
et al., 2005) (Dautzenberg & Jaeger, 2002) hence making EtBr
intercalation possible. The highly substituted di-quaternary
piperazine-chitosan, DQ56, did not increase the biding affin-
ity relative to DQ39 derivative, despite an increase in the
charge density of its polymer chain. Further studies are
needed to understand if a relative ‘stiffness’ of highly
charged DQ56 polymer molecules in solution due to the
effect of an increased number of ‘bulky’ pendant groups,
and/or the ‘charge densities matching’ considerations con-
tribute to this effect.
It should be noted that although non-quaternised deriva-
tives, NQ30 and NQ60, possess no permanent positive qua-
ternary charges on the piperazine ring, and hence could be
expected to be significantly inferior at complexing siRNA
than mono- and di-quaternary chitosans, the piperazine ring
contains two tertiary amines that can be protonated in solu-
tion, in addition to 10% ionization of unsubstituted chito-
san monomers at pH 7.4 (assuming pKa of 6.5) (Denuziere
et al., 1996). The first pKa of 1,4-dimethylpiperazine (structure
closely related to the substituent in NQ30 and NQ60) has
been previously reported to be around 8.4 (Khalili et al.,
2009), therefore at pH 7.4 90% of the piperazine amine
groups will be protonated, creating charge in NQ30 and
NQ60. The second pKa was measured to be around pH 3.8,
and hence this amine will not be appreciably protonated at
pH 7.4 to contribute to the overall charge density of the pol-
ymers under experimental conditions used in the siRNA
complexation. One also has to consider possible ‘local effects’
on ionization of piperazine amine groups in the vicinity of
siRNA as a strong polyelectrolyte, as we observed previously
(Ehtezazi et al., 2003).
Toxicity profiles of substituted chitosan derivatives
(Supporting information, Figures S2 and S3) demonstrate no
significant changes in cell metabolic activity up to 0.1mg/ml.
Two highly substituted mono-quaternary polymers, MQ1-85
and MQ4-87, have IC50 values around 0.9mg/ml, and di-qua-
ternary polymer with a high level of substitution, DQ56, has
an IC50 around 0.05mg/ml. For comparison, reported IC50 val-
ues for Lipofectamine and PEI are 0.05mg/ml (Wen et al.,
2004) and 6mg/ml (Merkel et al., 2011), respectively, whilst
application of a ‘non-modified’ chitosan with a comparable
molecular weight (Ultrasan 20–70 applied at pH 6.0 due to
chitosan’s low water solubility at physiological pH) caused a
73% reduction in viability at a concentration of 0.03mg/ml
(Casettari et al., 2010). Previous studies investigating the rela-
tionship between molecular weight (Mw) of chitosans, their
cytotoxicity, and their siRNA binding affinity showed that
‘non-modified’ chitosans with MW <50 kDa, similar to
molecular weight range of substituted chitosan used in this
study, form siRNA complexes with larger particle size and
poor transfection ability (Liu et al., 2007), or that those with
MW <20 kDa did not form siRNA complexes (Ragelle et al.,
2014). On the other hand, higher molecular weight chitosans,
shown capable of siRNA complexation, have been linked to
higher cytotoxicity (Huang et al., 2004). Despite their rela-
tively low-molecular weight, the piperazine-chitosans used in
the present study (MW 20–45 kDa) were capable of com-
plexing siRNA at relatively low monomer:nucleotide ratios;
improved binding can be attributed to the presence of the
piperazine substituents (with permanent quaternary positive
center in the MQ and DQ or two tertiary amines in NQ deriv-
atives), which also improve water solubility while maintaining
a relatively low cytotoxicity. It should be noted that ethidium
bromide displacement assay showed that there was little
benefit for the complexation of increasing the monomer:nu-
cleotide ratio above 5:1, particularly in the case of the DQ39
derivative, with gel electrophoresis showing an appearance
of excess of unbound, ‘free’ polymeric material above this
ratio (Figure 1(B)). Therefore, in subsequent in vitro and
in vivo studies, the monomer:nucleotide 5:1 ratio complexes
were used. Data from particle size analysis illustrate the for-
mation of nano-sized complexes of sub-300 nm diameter, for
all piperazine-substituted chitosans at an optimized mono-
mer:nucleotide ratio (Table S1), as well as a clear dependence
of the particle size and complexes colloidal stability on
monomer:nucleotide ratio (i.e. charge ratio, as per Table 1).
DQ39-siRNA complexes possessed average zeta potential
ofþ31mV (Figure S4). Figure S5 illustrates that complexed
siRNA can be released, with maintained integrity, from the
DQ39 complexes.
It should be noticed that, with the exception of DQ56, all
piperazine chitosans had an average charge density of less
than 1 positive charge per monomer (Table 1), hence low
levels of unbound charges would be present in the mono-
mer:nucleotide 5:1 complexes used. On the contrary, the
reports evaluating chitosan:siRNA complexes normally use
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high N:P ratios (N:P> 25, in some cases approaching 100:1)
(Katas & Alpar, 2006). Such formulations could bring signifi-
cant developability problems, including limited dosing and
the potential toxic effects and burden of excess chitosan
material. We hence propose that an additional comparative
advantage of piperazine-substituted chitosans lays in their
ability to form discrete, sub-300 nm sized complexes capable
of silencing effect (Figure 2) at relatively low monomer:nu-
cleotide ratios of 5:1. Although siRNA complexes with non-
and mono-quaternary polymers, NQ30, MQ1-46, and MQ4-42,
exhibited sub-30% gene silencing efficiencies (25%, 29%, and
28%, respectively), knockdown with the di-quaternary poly-
mer, DQ39, reached 80% level, relative to untreated H1299
cells, and was comparable to lipofectamine (Figure 2). This
gene silencing effect is substantial and compares favorably
with that reported recently for trimethylated chitosan/tripoly-
phosphate nanoparticles incorporating siRNA (Ni et al., 2018).
Analysis of silencing by siRNA:DQ39 polymer complexes in a
panel of lung cell lines (A549, Calu-3, and H1299), in relation
to the cell culture model and cellular trafficking, has been
described previously (Capel et al., 2016). With the aim of the
present study to investigate in vivo siRNA silencing potential
of piperazine-chitosans, DQ39 complexes with EGFR-siRNA
were evaluated in A549-luc transformed cells (Figure 2(B)),
subsequently used to establish the bioluminescent tumor
xenograft model in mice.
Data presented in Figure 2(B) indicate a time-dependent
cell survival; at 24 and 48 hours post DQ39-(EGFR)-siRNA
transfection, cell survival was reduced to 65% and 50%,
respectively. At 72 hours post-transfection, it recovered to
70% of untreated cells, indicating the optimal treatment
regime required for in vivo studies. Negative control siRNA
had no significant effects on cell survival at any time-point
(p> .05).
Developability potential of piperazine substituted soluble-
chitosans as enabling technology for inhalation-mediated
siRNA delivery was tested for nebulized formulation. Initially,
to achieve osmolarity of physiological saline (0.300 osmol/kg)
appropriate for inhalation, excipients (mannitol 4.6% w/v,
sucrose 8.4% w/v, or trehalose 10.3% w/v) were included into
the formation of DQ39-siRNA complexes and the aerolisation
properties assessed using microspayer (PennCenturyTM) – a
device utilized in intratracheal inhalation experiments in
animals.
Data from in vivo animal studies following administration
of the DQ39-siRNA complexes as aerosol via microsprayer
(PennCentury) in mice are illustrated in Figure 3. Aerosols
produced by this microsprayer have been demonstrated to
reach the lung periphery, in spite of the relatively large drop-
let size (similar as in Figure 3), and effectively preserve the
integrity and viability of biological materials (Bivas-Benita
et al., 2005). In a previous work, deposition siRNA complexes
following aerolisation by a microsprayer was assessed in
alveolar and bronchiolar tissue sections of the lung (Nielsen
et al., 2010), however, IVIS analysis used in this study pro-
vided a valuable information of the whole lung deposition
pattern. The data illustrate that siRNA distribution throughout
the lung does not appear homogeneous and that the depos-
ition pattern varies within the lung and between animals
(Figure 3). Unfortunately, following lung administration, we
were not able to detect the DY647-siRNA-DQ39 fluorescence
in the lung in whole, intact animals using IVIS imaging. We
hence imaged excised lungs for the deposition studies. The
possible reason may be low penetration of fluorescence
across coastal bones structures, despite a far-red emitter,
DY647 probe. This furthermore prevented the use of IVIS to
assess in vivo silencing of the complexes in an orthotopic
lung tumor model.
In vivo potential of piperazine chitosan complexes to
inhibit tumor growth through the silencing of EGFR was
therefore assessed in subcutaneous bioluminescent tumor
A540-luc xenograft model. Mice were treated twice weekly
via intratumoural injection with either DQ39-(EGFR)-siRNA or
DQ39-(negative control)-siRNA complexes for four weeks. The
effects of the treatments on tumor growth were monitored
by whole body in vivo bioluminescent imaging (IVIS). Data
are presented in terms of mean tumor bioluminescent
Figure 2. siRNA silencing with piperazine chitosan siRNA complexes. (A)
Piperazine chitosan silencing of GAPDH in H1299 cells by siRNA complexes with
different piperazine chitosan derivatives. Complexes (100 nM siRNA) were pre-
pared at a 5:1 monomer:nucleotide ratio and incubated with cells in serum free
RPMI-1640 medium for 4 hours and analysis performed 44 hours after com-
plexes removal and cells incubation in fresh RPMI-1640 medium containing
serum. GAPDH levels were evaluated using the KDalert GAPDH kit (Ambion)
and expressed as the % GAPDH reduction relative to expression in untreated
control cells. Data shown as the mean ± SD (n¼ 6). p< .001. (B) A549-luc
cellular survival in vitro. A549-luc cells were seeded in a 96-well plate at a dens-
ity of 104 cells/well. EGFR-siRNA or negative control siRNA complexes with
DQ39 (100 nM siRNA) were incubated with cells in serum-free medium for
4 hours. Samples were then removed and replaced with fresh serum-containing
growth medium. Cells were incubated for a further 24, 48, or 72 hours after
which cell survival was measured by an MTS assay. Doxorubicin (5 mM) was
incubated with cells for 24, 48, or 72 hours. Doxorubicin was used at the IC50
concentration (5 mM) as established for 48 hr incubation in the previous experi-
ment. Results are shown as the mean ± SD (n¼ 8).
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Figure 3. Typical droplet size analyses and spray pattern of DQ39-siRNA complexes sprays obtained by microsprayer (PennCenturyTM) and biodistribution of DY647-
labeled DQ39-siRNA complexes in the lung following microsprayer administration to mice. Spray pattern analysis (top images) used Para Red dye added to the buf-
fer for visualization purposes. Droplet size data (table) reported as volume diameter defined by 10%, 50%, and 90% (volume median) of the cumulative volume
undersize (Dv10, Dv5, and Dv90, respectively). Data is given as the mean ± SD (n¼ 3). Ovality was calculated as the ratio of maximum vs. minimum diameter, aver-
age of three sprays, as illustrated. Bottom images illustrate IVIS analysis of excised lung following application by a microsprayer of DY647-labeled siRNA complies
with DQ39 formulated at 5:1 ratio at siRNA concentration of 10 mg/50 ml. Mice were dosed with siRNA complexes (10 mg siRNA in 50 ml) and images of obtained by
IVIS imaging immediately after administration.
Figure 4. Tumour growth inhibition by EGFR-siRNA complexes with DQ39 piperazine-substituted chitosan. Images show luciferase bioluminscence of A549Luc cells
assessed by whole animal bioluminescent imaging (IVIS) of DQ39-(negative control)-siRNA (upper images) and DQ39-(EGFR)-siRNA complexes (lower images) at day
8, 1, 6, 13, 22, 27, and 34 of the treatment. IVIS images following one selected mouse per group are shown. Graph shows mean bioluminescent intensity relative
to pretreatment values.
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intensity (BLI) and typical IVIS images from one animal repre-
sentative of each treatment group at each time point
throughout the study (Figure 4). Prior to the therapy study,
acute tolerability of the siRNA, the delivery system, and doxo-
rubicin standard of care was assessed in tumor bearing mice
(two mice per treatment under dosing as per the therapy
study for 14 days, followed by cessation of dosing and obser-
vation for a further 14 days). No adverse effects were noted
in the tolerability study and subsequent therapy study.
Adverse effects (diarrhea, weakness, and severe weight loss)
were described in a previous study, which reported success-
ful inhibition of tumor growth on the treatment with EGFR
and VEGFR targeted siRNA complexed by PEI (Chen et al.,
2013). In our therapy study, administering DQ39-(EGFR)-siRNA
complexes, no such adverse effects were observed over
repeat dosing for four weeks.
The data illustrate that EGFR-siRNA complexes with DQ39
piperazine-substituted chitosan were able to inhibit tumor
growth, relative to negative control siRNA treatment. Further
analysis of the complexes’ silencing effect was conducted by
histological inspection of tumor xenografts extracted at the
final treatment time point (Figure 5). The data show that
administration of EGFR-siRNA complexes significantly inhib-
ited EGFR protein level, and support evidence from previous
work (Chen et al., 2013), although the reasons for maximum
silencing effect occurring at 20 days of the treatments are
not clear at present. It should be noted that the xenografts
were excised at the final time point, following day 34 of
Figure 5. Mouse xenograft models stained for EGFR. Samples of A549Luc xenograft mouse models excised at the final time point. Four xenograft samples from
each treatment group were stained for EGFR (two images of different fields of view shown for each xenograft). Images taken with a Leica DM4000B light micro-
scope at 10 magnification. Areas expressing EGFR are stained brown (darker regions in black and white copy). Graph shows H-scoring data, as explained in the
experimental section.
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treatment, and that hence they do not represent the point in
the treatment at approximately day 20 when the EGFR level
reduction was the most significant (Figure 5). It is therefore
important to notice that the EGFR levels were still signifi-
cantly reduced in tissue samples of animals treated with the
EGFR siRNA complexes, relative to negative control.
Conclusions
Piperazine substituted chitosans are, unlike unmodified chito-
san, freely soluble in water at physiological pH. They afford
an efficient complexation of siRNA into sub-300 nm colloidal
complexes, achieved at relatively low polymer to siRNA
monomer: nucleotide ratio of 5:1 for a DQ39 di-quaternary
derivative. Substituted chitosans possess low cytotoxicity,
with no significant reduction in cell viability up to 0.1mg/ml
concentration , in comparison to 0.03mg/ml for pure, lower
molecular weight chitosan (when applied dissolved at pH 6.0,
due to solubility issues). In vitro, the complexes ensure sig-
nificant silencing of 80% for best performing DQ39-siRNA
complexes. In vivo, the piperazine chitosan complexes did
not cause tolerability issues and achieve successful inhibition
of tumor growth in subcutaneous bioluminescent tumor
A540-luc xenograft model. Developability of the system as
aerosol formulation for inhalation delivery is also demon-
strated, illustrating a potential of modified chitosans to be
utilized as a safe system for delivery of siRNA.
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